Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinomaChuan Xing Wu, Tan To Cheung|Theranostics|2018Cited by 234